10x Genomics, Inc.

None of our directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended September 30, 2026, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:

On August 21, 2026, Sarah Teichmann, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 6,000 shares of the Company’s common stock, subject to certain conditions. The expiration date of the trading arrangement is August 6, 2027.

On August 27, 2026, Adam Taich, our Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 58,300 shares of the Company’s common stock, subject to certain conditions. The expiration date of the trading arrangement is December 31, 2027.

On August 28, 2026, Benjamin Hindson, our President, Chief Scientific Officer and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,021 shares of the Company’s common stock as well as additional shares of the Company’s common stock anticipated to be received from potential restricted stock units expected to vest between November 2026 and November 2027, subject to certain conditions. The expiration date of the trading arrangement is November 29, 2027.

On September 14, 2026, Sridhar Kosaraju, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,000 shares of the Company’s common stock, subject to certain conditions. The expiration date of the trading arrangement is May 14, 2027.